CataloniaBio & HealthTech and Boston MassMEDIC join forces Blog Post

CataloniaBio & HealthTech –the association of companies in the biomedicine and health arena in Catalonia, based in the Barcelona Science Park– and the Massachusetts Medical Device Industry Council (MassMEDIC), the largest association of medical technology companies in the United States, have signed an agreement to foster innovation and collaborations in business and research among their members. 

 

The hippocampus orchestrates the cerebral process that allows us to recall memories Blog Post

For the first time in humans, researchers from the Institute for Bioengineering of Catalonia (IBEC) at the Barcelona Science Park have simultaneously recorded the brain activity of the two key areas linked to memory: the hippocampus and the neocortex. This study was made possible thanks to the voluntary participation of epilepsy patients who, due to their disease, have intracranial electrode implants. Making use of virtual reality, the participants performed spatial memory tasks. 

 

Bionure launches a crowdfunding campaign to fund the preparation the phase 2 study of BN201 Blog Post

Bionure, a biotech company specialized in neuroprotection based in the Barcelona Science Park, has launched a crowdfunding campaign through the Spanish platform of Capital Cell with the objective of raising €1.3M that will be used to finance the preparation of the phase 2 study of its neuroprotectant BN201. The campaign (multiplesmotivos.com) is part of a bridge round of €2.4M that will cover the expenses of regulatory and technical preparation of the phase 2 study.

 

Ona Therapeutics hits the road thanks to Sabadell Asabys Blog Post

Today Ona Therapeutics, the new IRB Barcelona spin-off, announced the close of a seed funding round of € 1.5M given by Sabadell Asabys, a fund managed by Asabys Partners and devoted to investments in health innovation. With this injection of capital, the company, based in the Barcelona Science Park, will begin work on the development of a new drug for the treatment of metastatic cancer.

 

ODISSeA: a pioneer initiative to improve organ donation in Southeast Asian countries Blog Post

Promoting highly specialized training for experts in the field of organ donation in Southeast Asian countries is the main aim of the training program Train the trainers, to take place from May 13 to 17 in Barcelona, under the direction of Martí Manyalich, lecturer at the Faculty of Medicine and Health Sciences of the UB and president of the DTI Foundation – Donation & Transplantation Institute, located in the Barcelona Science Park. This training initiative for physicians is part of the ODISSeA project and will finish with an institutional ceremony to take place in the Aula Magna at the Faculty of Medicine and Health Sciences of the UB on Friday, May 17.

 

Bionure reports successful Phase 1 Study for lead candidate BN201 Blog Post

Bionure, a biotech company specialized in neuroprotection based in the Barcelona Science Park, today announces that it has successfully concluded its Phase 1 clinical study with its lead candidate BN201, a first-in-class compound to treat neurodegenerative diseases such as Multiple Sclerosis (MS). The company is now preparing a Series B funding round to finance the Phase 2 clinical program. 

 

The Bosch i Gimpera Foundation participates in five clusters in Catalonia Blog Post

The Bosch i Gimpera Foundation, based in the Barcelona Science Park, has joined the Catalan Kid’s Cluster. With the goal of encouraging contacts between research groups at the University of Barcelona and key economic players to transfer innovation to society, the foundation is also taking part in four more clusters in Catalonia: the Beauty Cluster Barcelona, the Advanced Materials Cluster of Catalonia, the Mental Health Cluster of Catalonia and the Food N’ Nutrition Cluster.  

 

Characterisation of the structure and function of a member of the L-Amino acid Transporter (LAT) family Blog Post

Scientists at the Institute for Research in Biomedicine (IRB Barcelona) in the Barcelona Science Park and the CIBER of Rare Diseases (CIBERER) – in collaboration with the Institute of Molecular Biology of Barcelona (IBMB-CSIC) at PCB, and the Barcelona Supercomputing Center-Centro Nacional de Supercomputación (BSC-CNS) – have now characterised the structure of a member of the LAT family. Mutations in L-amino acid transporters (LATs) can lead to a wide range of conditions, such as autism, hearing loss and aminoacidurias. The work has been published in the journal Nature Communications.

 

World’s first baby is born in Greece through of Maternal Spindle Transfer technique developed by Embryotools Blog Post

Through pioneering clinical research, Embryotools, based in the Barcelona Science Park, and Institute of Life in Athens have achieveg birth of the world’s first healthy baby through the pioneering Maternal Spindle Transfer method to solve infertility problems. This technique was implemented by the Greek IVF center and Spanish research center to address fertility issues associated with multiple in vitro fertilization (IVF) failures caused by cytoplasmic dysfunction of the oocytes or rare mitochondrial genetic diseases.

 

Dr. Cristina Bescos is new Managing Director of EIT Health Spain Blog Post

Dr. Cristina Bescos has been named the new Managing Director of EIT Health Spain, based in the Barcelona Science Park. She began her work 8 April 2019, after being approved by the EIT Health Spain Board to take over the position that had been held by Dr. Marco Pugliese since its creation in 2016. Her expertise and knowledge will continue to foster the main strategic areas covered by the partners of the Spanish node of EIT Health, the Knowledge and Innovation Community (KIC), dedicated to healthy living and active aging, promoted by the European Institute of Technology and Innovation (EIT).